Electroacupuncture for Neuropathic Pain
Trial Summary
What is the purpose of this trial?
This trial is testing if electroacupuncture, which uses needles and a small electrical current, can help reduce pain in cancer survivors who have pain from chemotherapy. Electroacupuncture has been studied for its potential to relieve cancer pain and improve quality of life in cancer patients.
Will I have to stop taking my current medications?
The trial requires that you stay on a stable regimen of your current pain medications, meaning you should not change your medication routine if you are already taking anti-neuropathy or other pain medications. You also cannot start any new pain medications during the first 12 weeks of the study.
What data supports the effectiveness of electroacupuncture for neuropathic pain?
Research suggests that electroacupuncture can significantly reduce pain intensity and improve quality of life for patients with neuropathic pain, as shown by a study where patients experienced a 46.7% reduction in pain intensity after eight sessions. Additionally, both acupuncture and TENS have been shown to help manage various types of pain by activating the body's natural pain control systems.12345
Is electroacupuncture generally safe for humans?
Electroacupuncture is generally considered safe when performed by trained professionals, but like other forms of acupuncture, it can have some risks. These include minor issues like local reactions or dizziness, and very rarely, more serious problems like infections or organ injuries. It's important to ensure that the practitioner follows proper safety guidelines, such as using clean needles.678910
How does electroacupuncture differ from other treatments for neuropathic pain?
Electroacupuncture is unique because it combines traditional acupuncture with electrical stimulation to reduce neuropathic pain by inhibiting astrocyte activation in the spinal cord, which is different from conventional drug treatments. It has shown promise in reducing pain intensity and improving psychosocial and functional outcomes, particularly for burning and electric shock-like pain.13111213
Research Team
Ting Bao, MD
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for English-speaking adults over 18 who have completed certain chemotherapy treatments at least three months ago and are experiencing nerve pain from it. They must not start any new pain medications during the first 12 weeks of the study and should be free of cancer as confirmed by exams and history.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 10 electroacupuncture or sham acupuncture treatments over 8 weeks
Follow-up
Participants are monitored for changes in pain severity and other CIPN-related symptoms
Treatment Details
Interventions
- Acupuncture (Behavioural Intervention)
- Electroacupuncture (Behavioural Intervention)
Acupuncture is already approved in China for the following indications:
- Pain management
- Hot flashes
- Fatigue
- Sleep disturbances
- Anxiety
- Depression
- Neuropathy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Dr. Benjamin L. Ebert
Dana-Farber Cancer Institute
Chief Executive Officer
MD from Harvard Medical School, PhD from Oxford University
Dr. Craig A. Bunnell
Dana-Farber Cancer Institute
Chief Medical Officer since 2012
MD from Harvard Medical School, MPH from Harvard School of Public Health, MBA from MIT Sloan School of Management
Memorial Sloan Kettering Cancer Center
Collaborator
Lisa M. DeAngelis
Memorial Sloan Kettering Cancer Center
Chief Medical Officer since 2021
MD from Columbia University
Selwyn M. Vickers
Memorial Sloan Kettering Cancer Center
Chief Executive Officer since 2022
MD from Johns Hopkins University